RxDoctor Payments Data

Rachel Espiritu, MD

Endocrinology, Diabetes & Metabolism · Akron, OHNPI 1982724639

Payments from drug & device makers

$6,280in general payments, 2019–2025

Across 64 payments — averaging $98.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$5K
  • Novo Nordisk$194
  • Medtronic$188
  • Amgen$181
  • Corcept Therapeutics$153
  • Lilly USA, LLC$81
  • plus $454 from 15 others

What the payments were for

  • Consulting fees$4,90878%
  • Food & beverage$1,34821%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,280 in reported general payments places this provider in the 70th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$58,755
Medicare patients
253
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide123$186,266
TrulicityDulaglutide138$178,444
Teriparatide42$102,945
MounjaroTirzepatide80$86,403
JardianceEmpagliflozin50$68,974
FarxigaDapagliflozin Propanediol46$56,995
TymlosAbaloparatide17$44,557
ProliaDenosumab27$43,954
Humalog Kwikpen U-200Insulin Lispro15$38,325
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog34$23,176
TradjentaLinagliptin20$17,731
Lantus SolostarInsulin Glargine,hum.Rec.Anlog100$16,380
Tresiba Flextouch U-200Insulin Degludec16$16,296
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$12,533
Insulin Lispro Kwikpen U-100Insulin Lispro32$12,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro$81$267,201238 claims
Novo NordiskOzempic, Novolog$194$188,142135 claims
AstraZenecaFarxiga$16$56,99546 claims
Radius Health, Inc.Tymlos$59$44,55717 claims
AmgenProlia$181$43,95427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →